Forte Change In Cash vs Ev To Free Cash Flow Analysis

FBRX Stock

USD 0.62 0.01 0.79%

Forte Biosciences financial indicator trend analysis is much more than just examining Forte Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Forte Biosciences is a good investment. Please check the relationship between Forte Biosciences Change In Cash and its Ev To Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Change In Cash vs Ev To Free Cash Flow

Change In Cash vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Forte Biosciences Change In Cash account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Forte Biosciences' Change In Cash and Ev To Free Cash Flow is -0.51. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Forte Biosciences, assuming nothing else is changed. The correlation between historical values of Forte Biosciences' Change In Cash and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Forte Biosciences are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Change In Cash i.e., Forte Biosciences' Change In Cash and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.51

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Change In Cash

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Forte Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Forte Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to drop to 855.00 in 2024

	2023	2024 (projected)
Depreciation And Amortization	9K	8.6K
Interest Income	1.1M	1.3M

Depreciation And Amortization Interest Income

Forte Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.52	0.55	0.64	0.83	0.7	-0.06	-0.74	0.57	0.33	0.69	-0.04	0.32	-0.38	1.0	0.92	-0.37	0.83	-0.38	0.45	-0.15	0.68	0.8	0.6	0.7	1.0
Short Long Term Debt Total	0.52		0.79	0.59	0.03	0.67	0.62	-0.56	0.56	-0.34	0.9	0.71	0.87	-0.32	0.49	0.32	-0.52	0.68	-0.32	0.9	-0.64	0.66	0.62	0.91	0.67	0.49
Other Current Liab	0.55	0.79		0.93	0.13	0.77	0.35	-0.81	0.74	-0.09	0.84	0.38	0.62	-0.45	0.52	0.25	-0.38	0.47	-0.45	0.58	-0.29	0.7	0.68	0.82	0.77	0.52
Total Current Liabilities	0.64	0.59	0.93		0.31	0.75	0.2	-0.84	0.75	0.04	0.7	0.09	0.4	-0.58	0.62	0.35	-0.35	0.49	-0.58	0.41	-0.13	0.74	0.62	0.72	0.75	0.62
Total Stockholder Equity	0.83	0.03	0.13	0.31		0.35	-0.49	-0.53	0.24	0.6	0.25	-0.44	-0.15	-0.22	0.85	0.88	0.04	0.54	-0.22	-0.08	0.17	0.34	0.6	0.06	0.35	0.85
Property Plant And Equipment Net	0.7	0.67	0.77	0.75	0.35		0.06	-0.77	0.97	0.23	0.88	0.13	0.32	-0.04	0.68	0.54	-0.33	0.48	-0.04	0.62	0.09	0.54	0.76	0.77	1.0	0.68
Net Debt	-0.06	0.62	0.35	0.2	-0.49	0.06		-0.06	0.04	-0.93	0.29	0.66	0.77	-0.4	-0.09	-0.18	-0.4	0.42	-0.4	0.67	-0.79	0.57	-0.02	0.6	0.06	-0.08
Retained Earnings	-0.74	-0.56	-0.81	-0.84	-0.53	-0.77	-0.06		-0.73	-0.13	-0.7	0.11	-0.27	0.32	-0.72	-0.6	-0.02	-0.53	0.32	-0.31	0.0	-0.72	-0.88	-0.57	-0.78	-0.73
Accounts Payable	0.57	0.56	0.74	0.75	0.24	0.97	0.04	-0.73		0.21	0.78	0.05	0.19	0.0	0.55	0.39	-0.25	0.32	0.0	0.52	0.22	0.48	0.64	0.7	0.97	0.55
Cash	0.33	-0.34	-0.09	0.04	0.6	0.23	-0.93	-0.13	0.21		0.04	-0.49	-0.54	0.31	0.35	0.37	0.11	-0.18	0.31	-0.38	0.68	-0.37	0.26	-0.28	0.23	0.35
Non Current Assets Total	0.69	0.9	0.84	0.7	0.25	0.88	0.29	-0.7	0.78	0.04		0.52	0.68	-0.14	0.66	0.48	-0.51	0.62	-0.14	0.8	-0.31	0.62	0.8	0.89	0.88	0.67
Non Currrent Assets Other	-0.04	0.71	0.38	0.09	-0.44	0.13	0.66	0.11	0.05	-0.49	0.52		0.84	-0.13	-0.07	-0.25	-0.59	0.26	-0.13	0.72	-0.74	0.21	0.04	0.58	0.13	-0.06
Other Assets	0.32	0.87	0.62	0.4	-0.15	0.32	0.77	-0.27	0.19	-0.54	0.68	0.84		-0.42	0.29	0.13	-0.65	0.64	-0.42	0.84	-0.87	0.63	0.38	0.81	0.31	0.3
Long Term Debt	-0.38	-0.32	-0.45	-0.58	-0.22	-0.04	-0.4	0.32	0.0	0.31	-0.14	-0.13	-0.42		-0.38	-0.18	0.41	-0.56	1.0	-0.19	0.58	-0.62	-0.05	-0.38	-0.04	-0.39
Cash And Short Term Investments	1.0	0.49	0.52	0.62	0.85	0.68	-0.09	-0.72	0.55	0.35	0.66	-0.07	0.29	-0.38		0.93	-0.36	0.82	-0.38	0.42	-0.13	0.67	0.79	0.57	0.68	1.0
Common Stock Total Equity	0.92	0.32	0.25	0.35	0.88	0.54	-0.18	-0.6	0.39	0.37	0.48	-0.25	0.13	-0.18	0.93		-0.18	0.78	-0.18	0.31	-0.03	0.53	0.74	0.37	0.54	0.93
Common Stock Shares Outstanding	-0.37	-0.52	-0.38	-0.35	0.04	-0.33	-0.4	-0.02	-0.25	0.11	-0.51	-0.59	-0.65	0.41	-0.36	-0.18		-0.54	0.41	-0.72	0.52	-0.37	-0.07	-0.7	-0.33	-0.36
Short Term Investments	0.83	0.68	0.47	0.49	0.54	0.48	0.42	-0.53	0.32	-0.18	0.62	0.26	0.64	-0.56	0.82	0.78	-0.54		-0.56	0.69	-0.61	0.81	0.59	0.72	0.48	0.83
Long Term Debt Total	-0.38	-0.32	-0.45	-0.58	-0.22	-0.04	-0.4	0.32	0.0	0.31	-0.14	-0.13	-0.42	1.0	-0.38	-0.18	0.41	-0.56		-0.19	0.58	-0.62	-0.05	-0.38	-0.04	-0.39
Non Current Liabilities Total	0.45	0.9	0.58	0.41	-0.08	0.62	0.67	-0.31	0.52	-0.38	0.8	0.72	0.84	-0.19	0.42	0.31	-0.72	0.69	-0.19		-0.61	0.58	0.43	0.93	0.62	0.42
Capital Surpluse	-0.15	-0.64	-0.29	-0.13	0.17	0.09	-0.79	0.0	0.22	0.68	-0.31	-0.74	-0.87	0.58	-0.13	-0.03	0.52	-0.61	0.58	-0.61		-0.5	-0.06	-0.51	0.09	-0.13
Other Current Assets	0.68	0.66	0.7	0.74	0.34	0.54	0.57	-0.72	0.48	-0.37	0.62	0.21	0.63	-0.62	0.67	0.53	-0.37	0.81	-0.62	0.58	-0.5		0.62	0.76	0.54	0.68
Other Stockholder Equity	0.8	0.62	0.68	0.62	0.6	0.76	-0.02	-0.88	0.64	0.26	0.8	0.04	0.38	-0.05	0.79	0.74	-0.07	0.59	-0.05	0.43	-0.06	0.62		0.58	0.76	0.79
Total Liab	0.6	0.91	0.82	0.72	0.06	0.77	0.6	-0.57	0.7	-0.28	0.89	0.58	0.81	-0.38	0.57	0.37	-0.7	0.72	-0.38	0.93	-0.51	0.76	0.58		0.77	0.57
Property Plant And Equipment Gross	0.7	0.67	0.77	0.75	0.35	1.0	0.06	-0.78	0.97	0.23	0.88	0.13	0.31	-0.04	0.68	0.54	-0.33	0.48	-0.04	0.62	0.09	0.54	0.76	0.77		0.68
Total Current Assets	1.0	0.49	0.52	0.62	0.85	0.68	-0.08	-0.73	0.55	0.35	0.67	-0.06	0.3	-0.39	1.0	0.93	-0.36	0.83	-0.39	0.42	-0.13	0.68	0.79	0.57	0.68

Click cells to compare fundamentals

Forte Biosciences Account Relationship Matchups

Forte Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.7M	61.2M	43.3M	42.0M	39.0M	43.2M
Other Current Liab	343.2K	1.0M	812K	2.0M	2.2M	4.0M
Total Current Liabilities	1.9M	2.3M	1.8M	3.2M	3.7M	6.0M
Total Stockholder Equity	(4.8M)	59.0M	41.5M	38.8M	35.3M	42.2M
Property Plant And Equipment Net	4.0M	150.6K	97K	0.0	109K	103.6K
Net Debt	1.8M	(58.8M)	(42.0M)	(41.1M)	(12.0M)	(12.6M)
Retained Earnings	(5.0M)	(51.5M)	(73.2M)	(87.0M)	(118.5M)	(124.4M)
Accounts Payable	1.6M	1.2M	946K	1.2M	1.4M	1.3M
Cash	6.9M	58.8M	42.0M	41.1M	12.0M	11.4M
Non Current Assets Total	150.6K	1.3M	786K	486K	653.0K	620.3K
Other Assets	227K	1.4M	0.0	1.0	0.9	0.86
Cash And Short Term Investments	6.9M	58.8M	42.0M	41.1M	37.1M	41.0M
Common Stock Total Equity	20K	23K	1K	13K	11.7K	9.9K
Common Stock Shares Outstanding	2.1M	7.4M	14.0M	17.4M	31.6M	33.1M
Short Term Investments	52.8M	55.3M	12.8M	25.2M	22.6M	29.7M
Liabilities And Stockholders Equity	7.7M	61.2M	43.3M	42.0M	39.0M	43.2M
Non Current Liabilities Total	28.4M	10.5M	1.2M	946K	1.2M	0.0
Other Current Assets	53.2K	76K	88K	70K	1.2M	672.5K
Other Stockholder Equity	(10.3M)	110.4M	114.7M	125.8M	153.8M	105.4M
Total Liab	12.4M	2.3M	1.8M	3.2M	3.7M	3.5M
Property Plant And Equipment Gross	4.0M	150.6K	97K	0.0	118K	112.1K
Total Current Assets	7.5M	59.9M	42.5M	41.5M	38.3M	41.8M
Accumulated Other Comprehensive Income	10K	(61.2M)	(43.3M)	4K	3.6K	3.8K
Common Stock	23K	1K	13K	21K	36K	37.8K
Property Plant Equipment	1.2M	4.0M	152K	97K	87.3K	82.9K
Net Tangible Assets	(4.8M)	59.0M	41.5M	38.8M	44.6M	29.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Forte Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Forte Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Forte Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Forte Biosciences Stock:

How To Invest In Forte

Details

Is Forte Stock a good investment?

Details

What is Forte Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Complementary Tools for Forte Stock analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.

	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Share Portfolio Track or share privately all of your investments from the convenience of any device

Is Forte Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Forte Biosciences. If investors know Forte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Forte Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Return On Assets

(0.61)

Return On Equity

(1.04)

The market value of Forte Biosciences is measured differently than its book value, which is the value of Forte that is recorded on the company's balance sheet. Investors also form their own opinion of Forte Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Forte Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Forte Biosciences' market value can be influenced by many factors that don't directly affect Forte Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Forte Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Forte Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Forte Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Forte Change In Cash vs Ev To Free Cash Flow Analysis

Change In Cash vs Ev To Free Cash Flow

Change In Cash vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Change In Cash

Ev To Free Cash Flow

Forte Biosciences fundamental ratios Correlations

Forte Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Forte Biosciences fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Forte Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Assets	+ 1.0	Cash And Short Term Investments
Accounts Payable	+ 0.97	Property Plant And Equipment Net

Cash	- 0.93	Net Debt
Other Stockholder Equity	- 0.88	Retained Earnings
Capital Surpluse	- 0.87	Other Assets
Retained Earnings	- 0.84	Total Current Liabilities
Retained Earnings	- 0.81	Other Current Liab
Capital Surpluse	- 0.79	Net Debt